Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Telo Genomics Corp V.TELO

Alternate Symbol(s):  TDSGF

Healthcare Industrials Biotechnology Conglomerates
Telo Genomics Corp. is a biotech company pioneering the telomere platform in the industry with applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. The Company's lead application, TELO-MM is being developed to provide actionable information to medical professionals in the treatment of multiple myeloma, a form of... see more

Recent & Breaking News (TSXV:TELO)

3D Signatures Reports Financial Results for 2017

GlobeNewswire October 24, 2017

3D Signatures Announces Changes to Its Board of Directors and Audit Committee

GlobeNewswire October 19, 2017

3D Signatures Announces Completion of Stage 3 of Hodgkin’s Lymphoma Test Validation Program

GlobeNewswire October 10, 2017

3D Signatures Announces Change to Its Board of Directors

GlobeNewswire October 10, 2017

3D Signatures Announces Close of Private Placement With Strategic Partner and Prospectus Update

GlobeNewswire October 4, 2017

3D Signatures Announces Private Placement With Strategic Partner and Prospectus Update

GlobeNewswire October 3, 2017

3D Signatures Announces Change to Its Board of Directors

GlobeNewswire August 11, 2017

3D Signatures Inc. Announces Short Form Prospectus Offering to Raise Up to C$5 Million

MarketWire Canada July 19, 2017

3D Signatures Inc. Announces Grant of Stock Options

GlobeNewswire June 27, 2017

3D Signatures Advances Hodgkin’s Lymphoma Test

GlobeNewswire June 8, 2017

3D Signatures Inc. Reports Third Quarter 2017 Financial Results

GlobeNewswire May 31, 2017

3D Signatures Announces Change to Its Board of Directors

GlobeNewswire May 5, 2017

3D Signatures Receives First Prostate Cancer Blood Samples for Precise Clinical Trial

GlobeNewswire April 27, 2017

3D Signatures Announces Relocation to MaRS Discovery District in Toronto

GlobeNewswire April 18, 2017

3D Signatures Announces Appointment of Dr. Kevin Little as Chief Scientific Officer

GlobeNewswire April 11, 2017

3D Signatures Completes Assay Validation for Hodgkin’s Lymphoma Test

GlobeNewswire March 29, 2017

3D Signatures’ TeloView™ Software Identifies and Stages Patients With Alzheimer’s Disease From a Cheek Swab

GlobeNewswire March 21, 2017

3D Signatures Makes Final Patent Payment

GlobeNewswire March 14, 2017

3D Signatures Inc. Reports Second Quarter 2017 Financial Results

GlobeNewswire March 2, 2017

3D Signatures Inc. Initiates Hodgkin’s Lymphoma Validation Program

GlobeNewswire February 23, 2017